0000771856false00007718562024-10-032024-10-03


UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 

 
FORM 8-K
 
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported): October 3, 2024
 
CHAMPIONS ONCOLOGY, INC.
 
(Exact name of registrant as specified in its charter)
 
Delaware 001-11504 52-1401755
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation)   Identification No.)
 
1 University Plaza, Suite 307, Hackensack, New Jersey 07601
(Address of Principal Executive Offices)
 
Registrant’s telephone number, including area code: (201) 808-8400
 
N/A
(Former Name or Former Address if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act
Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per shareCSBRThe Nasdaq Stock Market LLC







Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



INFORMATION TO BE INCLUDED IN THE REPORT

 
Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Champions Oncology, Inc. deeply regrets to announce that its President, Mr. Brady Davis, passed away unexpectedly this week. Mr. Davis had served as its President since October 2023. Mr. Davis was a valued member of the Management team and will be greatly missed.




SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
  CHAMPIONS ONCOLOGY, INC.
  (Registrant)
   
Date: October 3, 2024By:/s/ Ronnie Morris 
  Ronnie Morris 
  Chief Executive Officer 
 

v3.24.3
Cover Page
Oct. 03, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Oct. 03, 2024
Entity Registrant Name CHAMPIONS ONCOLOGY, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-11504
Entity Tax Identification Number 52-1401755
Entity Address, Address Line One 1 University Plaza, Suite 307
Entity Address, City or Town Hackensack
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07601
City Area Code 201
Local Phone Number 808-8400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0000771856
Amendment Flag false
Document Information [Line Items]  
Document Period End Date Oct. 03, 2024
Champions Oncology (NASDAQ:CSBR)
Historical Stock Chart
From Dec 2024 to Dec 2024 Click Here for more Champions Oncology Charts.
Champions Oncology (NASDAQ:CSBR)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Champions Oncology Charts.